Results 11 to 20 of about 5,186 (110)

The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT Quizartinib is an oral, potent, selective FMS‐like tyrosine kinase 3 (FLT3) inhibitor, approved for the treatment of FLT3‐internal tandem duplication (ITD)–positive acute myeloid leukemia (AML) and under investigation in patients with newly diagnosed FLT3‐ITD–negative AML.
Yoo Y, Zahir H, Inaba S, Koo K, Garimella T, Abutarif M, Zheng M, Kamiyama E, Xu Y.   +8 more
europepmc   +2 more sources

The Effects of Drugs on CYP3A Enzyme Activity and Protein Expression Through Ubiquitination Modification Regulation. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Cytochrome P450 3A4 (CYP3A4) is one of the most important members of the cytochrome P450 subfamily, which is involved in the catalytic process of many drug activation or deactivation. Meanwhile, it is also a risk factor for drug‐induced toxic reactions.
Wang F, Gu X, Hong H, Xia Q, Zhang Y, Song Y, Li B, Fan P.   +7 more
europepmc   +2 more sources

Combined donor–recipient CYP3A functional allele count as an independent predictor of tacrolimus pharmacokinetics after liver transplantation

Frontiers in Pharmacology
BackgroundTacrolimus (TAC) exhibits high pharmacokinetic variability post-liver transplantation (LT). Traditional models overlook the metabolic chimerism between recipient (intestinal) and donor (hepatic) genotypes.
Luis Ramudo-Cela, Luis Ramudo-Cela, Brais Muñiz-Castro, Brais Muñiz-Castro, Francisco Suárez-López, Alejandra Otero-Ferreiro, Gilberto Pérez, Gilberto Pérez, José Santos, José Santos, Pedro Cabalar, Luis Margusino-Framiñán, Luis Margusino-Framiñán   +12 more
doaj   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, EarlyView.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Update of the risk assessment on emerging and novel brominated flame retardants in food

EFSA Journal, Volume 24, Issue 7, July 2026.
Abstract The European Commission asked EFSA to update its 2012 risk assessment on Emerging and Novel brominated flame retardants (BFRs) in food. Since the previous Opinion, further information was collected for a total of 27 BFRs. The CONTAM Panel concluded that TDBPP, DBPNG and TBNPA are considered genotoxic and carcinogenic.
EFSA Panel on Contaminants in the Food Chain (CONTAM), Helle Katrine Knutsen, Agneta Åkesson, Vasileios Bampidis, Margherita Bignami, Laurent Bodin, James Kevin Chipman, Gisela Degen, Antonio Hernández‐Jerez, Tim Hofer, Christer Hogstrand, Stefano Landi, Jean‐Charles Leblanc, Kyriaki Machera, Evangelia Ntzani, Isabelle P. Oswald, Guido Rychen, Salomon Sand, Katharina Vejdovszky, Barbara Viviani, Emilio Benfenati, Diane Benford, Andy Hart, Martin Rose, Henri Schroeder, Christiane Vleminckx, Martine Vrijheid, Edoardo Carnesecchi, Violetta Costanzo, Andrea Gissi, Eirini Kouloura, Luisa Ramos Bordajandi, Francesca Riolo, Christer Hogstrand   +33 more
wiley   +1 more source

Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice

Molecules
Exemestane, a steroidal aromatase inhibitor prescribed for post-menopausal women with estrogen receptor-positive breast cancer, is associated with debilitating musculoskeletal side effects and exhibits considerable interindividual variability in systemic
Hanieh Taheri, Eman Ahmed, Peng Hu, Alex Sparreboom, Shuiying Hu   +4 more
doaj   +1 more source

Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics

Pharmacology Research & Perspectives
Human cytochrome P450 3A4 (CYP3A4) is a drug‐metabolizing enzyme that is abundantly expressed in the liver and intestine. It is an important issue whether compounds of interest affect the expression of CYP3A4 because more than 30% of commercially ...
Genki Minegishi, Yuka Kobayashi, Mayu Fujikura, Ayane Sano, Yasuhiro Kazuki, Kaoru Kobayashi   +5 more
doaj   +1 more source

Harnessing Phytochemicals for Brain Cancer Therapy: Insights Into Medulloblastoma and Glioblastoma Treatment

Phytochemical Analysis, Volume 37, Issue 4, Page 507-535, June 2026.
ABSTRACT Primary brain tumors are life‐threatening diseases. Glioblastoma is the most aggressive type with a poor prognosis. Medulloblastoma is the most common pediatric brain tumor. While surgical treatments often result in recurrences owing to the complex nature of the tumor microenvironment, conventional treatments lower the quality of life of ...
Ilkay Irem Ozbek, Mesra Aktas, Hale Saybasili, Kutlu O. Ulgen   +3 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1287-1308, May 2026.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

Pharmacogenomics and Personalized Medicine, 2019
Laith N AL-Eitan1,2, Islam M Al-Dalalah1, Mohamed M Mustafa3, Mansour A Alghamdi4, Afrah K Elshammari5, Wael H Khreisat5, Mohammed N Al-Quasmi6, Hanan A Aljamal1 1Department of Applied Biological Sciences, Jordan University of Science and Technology ...
AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA   +7 more
doaj